Biosimilar infliximab use in paediatric IBD

BACKGROUND: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arch Dis Child
Main Authors: Richmond, Lisa, Curtis, Lee, Garrick, Victoria, Rogers, Pam, Wilson, Michelle, Tayler, Rachel, Henderson, Paul, Hansen, Richard, Wilson, David C, Russell, Richard K
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Drug Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754881/
https://ncbi.nlm.nih.gov/pubmed/28988215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/archdischild-2017-313404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados